Submitted by Anonymous (not verified) on 5 March 2025 - 13:20
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 26, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 26, Status: Authorised